Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Lumry

Showing results (71-80 of 139) with videos related to

Pageof 14
Sort By:
Immunotherapy|October 18, 2019
Immune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: an open-label, Phase III studyJohn W Sleasman, William R Lumry, Iftikhar Hussain, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 30, 2018
Long-term prophylaxis therapy in patients with hereditary angioedema with C1 inhibitor deficiencyTimothy Craig, Paula Busse, Richard G Gower, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 20, 2023
Lanadelumab in Patients 2 to Less Than 12 Years Old With Hereditary Angioedema: Results From the Phase 3 SPRING StudyMarcus Maurer, William R Lumry, H Henry Li, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 23, 2015
Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacksTimothy J Craig, H Henry Li, Marc Riedl, et al.
Allergy and Asthma Proceedings|November 25, 2024
Management of hereditary angioedema attacks by patients on long-term prophylaxis versus on-demand therapy onlyWilliam R Lumry, Anete S Grumach, Stephen D Betschel, et al.
The Journal of Allergy and Clinical Immunology|December 26, 2024
Interplay between on-demand treatment trials for hereditary angioedema and treatment guidelinesDanny M Cohn, Daniel F Soteres, Timothy J Craig, et al.
Allergy|May 27, 2020
Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacksMarc A Riedl, Marcus Maurer, Jonathan A Bernstein, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 4, 2013
Analysis of hereditary angioedema attacks requiring a second dose of ecallantideH Henry Li, Marilyn Campion, Timothy J Craig, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|January 25, 2026
Attack rate reductions following berotralstat initiation among US patients with hereditary angioedema in the real-worldMark Davis-Lorton, Raffi Tachdjian, Lorena Lopez-Gonzalez, et al.
Allergy|December 1, 2020
Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP studyWilliam R Lumry, Karsten Weller, Markus Magerl, et al.
Pageof 14

Showing results (71-80 of 139) with videos related to

Sort By:
Pageof 14
Immunotherapy|October 18, 2019
Immune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: an open-label, Phase III studyJohn W Sleasman, William R Lumry, Iftikhar Hussain, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|July 30, 2018
Long-term prophylaxis therapy in patients with hereditary angioedema with C1 inhibitor deficiencyTimothy Craig, Paula Busse, Richard G Gower, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 20, 2023
Lanadelumab in Patients 2 to Less Than 12 Years Old With Hereditary Angioedema: Results From the Phase 3 SPRING StudyMarcus Maurer, William R Lumry, H Henry Li, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 23, 2015
Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacksTimothy J Craig, H Henry Li, Marc Riedl, et al.
Allergy and Asthma Proceedings|November 25, 2024
Management of hereditary angioedema attacks by patients on long-term prophylaxis versus on-demand therapy onlyWilliam R Lumry, Anete S Grumach, Stephen D Betschel, et al.
The Journal of Allergy and Clinical Immunology|December 26, 2024
Interplay between on-demand treatment trials for hereditary angioedema and treatment guidelinesDanny M Cohn, Daniel F Soteres, Timothy J Craig, et al.
Allergy|May 27, 2020
Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacksMarc A Riedl, Marcus Maurer, Jonathan A Bernstein, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 4, 2013
Analysis of hereditary angioedema attacks requiring a second dose of ecallantideH Henry Li, Marilyn Campion, Timothy J Craig, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|January 25, 2026
Attack rate reductions following berotralstat initiation among US patients with hereditary angioedema in the real-worldMark Davis-Lorton, Raffi Tachdjian, Lorena Lopez-Gonzalez, et al.
Allergy|December 1, 2020
Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP studyWilliam R Lumry, Karsten Weller, Markus Magerl, et al.
Pageof 14